Loading...

We've got a brand new version of Simply Wall St! Try it out

C4X Discovery Holdings

AIM:C4XD
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
C4XD
AIM
£26M
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

C4X Discovery Holdings plc operates as a drug discovery and development company in the United Kingdom. The last earnings update was 110 days ago. More info.


Add to Portfolio Compare Print
C4XD Share Price and Events
7 Day Returns
6%
AIM:C4XD
-2.2%
GB Life Sciences
-1.7%
GB Market
1 Year Returns
-53.2%
AIM:C4XD
-0.8%
GB Life Sciences
-5.7%
GB Market
C4XD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
C4X Discovery Holdings (C4XD) 6% -7.3% -11% -53.2% -60.4% -
GB Life Sciences -2.2% -0.4% -0.6% -0.8% 19.3% 25.5%
GB Market -1.7% -4.6% -3.2% -5.7% 4% 0.2%
1 Year Return vs Industry and Market
  • C4XD underperformed the Life Sciences industry which returned -0.8% over the past year.
  • C4XD underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -5.7% over the past year.
Price Volatility
C4XD
Industry
5yr Volatility vs Market

Value

 Is C4X Discovery Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of C4X Discovery Holdings to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for C4X Discovery Holdings.

AIM:C4XD Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-01-31) in GBP £ 0.185
Payout Ratio Company Filings (2019-01-31) 0%
Discount Rate (Cost of Equity) See below 8.8%
Perpetual Growth Rate 10-Year GB Government Bond Rate 1.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for AIM:C4XD
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 1.2%
Equity Risk Premium S&P Global 6.7%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.01
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.01 (1 + (1- 19%) (0%))
1.132
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.23% + (1.132 * 6.65%)
8.76%

Discounted Cash Flow Calculation for AIM:C4XD using Dividend Discount Model Model

The calculations below outline how an intrinsic value for C4X Discovery Holdings is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

AIM:C4XD Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= £0.19 / (8.76% - 1.23%)
£2.46
AIM:C4XD Discount to Share Price
Calculation Result
Value per share (GBP) From above. £2.46
Current discount Discount to share price of £0.45
= -1 x (£0.45 - £2.46) / £2.46
81.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price C4X Discovery Holdings is available for.
Intrinsic value
>50%
Share price is £0.45 vs Future cash flow value of £2.46
Current Discount Checks
For C4X Discovery Holdings to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • C4X Discovery Holdings's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • C4X Discovery Holdings's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for C4X Discovery Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are C4X Discovery Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:C4XD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in GBP £-0.05
AIM:C4XD Share Price ** AIM (2019-08-16) in GBP £0.45
Europe Life Sciences Industry PE Ratio Median Figure of 16 Publicly-Listed Life Sciences Companies 38.35x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 793 Publicly-Listed Companies 15.83x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of C4X Discovery Holdings.

AIM:C4XD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:C4XD Share Price ÷ EPS (both in GBP)

= 0.45 ÷ -0.05

-8.9x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • C4X Discovery Holdings is loss making, we can't compare its value to the Europe Life Sciences industry average.
  • C4X Discovery Holdings is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does C4X Discovery Holdings's expected growth come at a high price?
Raw Data
AIM:C4XD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.9x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Life Sciences Industry PEG Ratio Median Figure of 11 Publicly-Listed Life Sciences Companies 2.34x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 570 Publicly-Listed Companies 1.41x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for C4X Discovery Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on C4X Discovery Holdings's assets?
Raw Data
AIM:C4XD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in GBP £0.22
AIM:C4XD Share Price * AIM (2019-08-16) in GBP £0.45
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry PB Ratio Median Figure of 12 Publicly-Listed Life Sciences Companies 2.05x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,370 Publicly-Listed Companies 1.39x
AIM:C4XD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:C4XD Share Price ÷ Book Value per Share (both in GBP)

= 0.45 ÷ 0.22

2.01x

* Primary Listing of C4X Discovery Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • C4X Discovery Holdings is good value based on assets compared to the GB Life Sciences industry average.
X
Value checks
We assess C4X Discovery Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. C4X Discovery Holdings has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is C4X Discovery Holdings expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-121.9%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is C4X Discovery Holdings expected to grow at an attractive rate?
  • Unable to compare C4X Discovery Holdings's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare C4X Discovery Holdings's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
  • C4X Discovery Holdings's revenues are expected to decrease over the next 1-3 years, this is below the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
AIM:C4XD Future Growth Rates Data Sources
Data Point Source Value (per year)
AIM:C4XD Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts -121.9%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 17.8%
United Kingdom of Great Britain and Northern Ireland Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average -6.7%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 12.1%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 4.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:C4XD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:C4XD Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-07-31 0 1
2020-07-31 0 -12 1
2019-07-31 0 -12 1
AIM:C4XD Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-01-31 7 -2 -3
2018-10-31 7 -1 -2
2018-07-31 7 0 -1
2018-04-30 4 -4 -4
2018-01-31 0 -7 -7
2017-10-31 0 -7 -7
2017-07-31 0 -7 -7
2017-04-30 0 -7 -6
2017-01-31 0 -7 -6
2016-10-31 0 -7 -5
2016-07-31 0 -6 -5
2016-04-30 0 -5 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if C4X Discovery Holdings is high growth as no earnings estimate data is available.
  • C4X Discovery Holdings's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:C4XD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from C4X Discovery Holdings Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:C4XD Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-07-31
2020-07-31
2019-07-31
AIM:C4XD Past Financials Data
Date (Data in GBP Millions) EPS *
2019-01-31 -0.05
2018-10-31 -0.04
2018-07-31 -0.02
2018-04-30 -0.09
2018-01-31 -0.16
2017-10-31 -0.17
2017-07-31 -0.17
2017-04-30 -0.17
2017-01-31 -0.16
2016-10-31 -0.17
2016-07-31 -0.17
2016-04-30 -0.16

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if C4X Discovery Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess C4X Discovery Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
C4X Discovery Holdings has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has C4X Discovery Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare C4X Discovery Holdings's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • C4X Discovery Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare C4X Discovery Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare C4X Discovery Holdings's 1-year growth to the Europe Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
C4X Discovery Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from C4X Discovery Holdings Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:C4XD Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 7.06 -2.50 2.79 8.54
2018-10-31 7.06 -1.82 2.70 7.77
2018-07-31 7.06 -1.14 2.61 6.99
2018-04-30 3.56 -4.27 2.68 6.72
2018-01-31 0.07 -7.40 2.76 6.44
2017-10-31 0.10 -7.09 2.65 6.27
2017-07-31 0.14 -6.78 2.53 6.10
2017-04-30 0.17 -6.21 2.17 5.81
2017-01-31 0.19 -5.64 1.80 5.51
2016-10-31 0.24 -5.48 1.78 5.38
2016-07-31 0.28 -5.32 1.75 5.24
2016-04-30 0.29 -5.05 1.55 5.10
2016-01-31 0.30 -4.78 1.35 4.96
2015-10-31 0.31 -3.92 1.13 4.06
2015-07-31 0.31 -3.06 0.90 3.16
2015-04-30 0.34 -2.45 0.86 2.39
2015-01-31 0.36 -1.84 0.82 1.63
2014-10-31 0.49 -1.48 0.73 1.40
2014-07-31 0.62 -1.12 0.64 1.18
2013-07-31 0.74 -0.48 1.32

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if C4X Discovery Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if C4X Discovery Holdings has efficiently used its assets last year compared to the Europe Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if C4X Discovery Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess C4X Discovery Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
C4X Discovery Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is C4X Discovery Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up C4X Discovery Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • C4X Discovery Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • C4X Discovery Holdings has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of C4X Discovery Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • C4X Discovery Holdings has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from C4X Discovery Holdings Company Filings, last reported 6 months ago.

AIM:C4XD Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 12.81 0.00 9.19
2018-10-31 12.81 0.00 9.19
2018-07-31 8.17 0.00 5.58
2018-04-30 8.17 0.00 5.58
2018-01-31 5.53 0.00 1.39
2017-10-31 5.53 0.00 1.39
2017-07-31 9.06 0.00 6.03
2017-04-30 9.06 0.00 6.03
2017-01-31 6.05 0.00 2.19
2016-10-31 6.05 0.00 2.19
2016-07-31 4.31 0.00 1.33
2016-04-30 4.31 0.00 1.33
2016-01-31 5.27 0.00 5.02
2015-10-31 5.27 0.00 5.02
2015-07-31 7.97 0.00 7.49
2015-04-30 7.97 0.00 7.49
2015-01-31 10.05 0.00 9.42
2014-10-31 10.05 0.00 9.42
2014-07-31 -1.33 2.26 0.67
2013-07-31 -0.24 2.14 1.51
  • C4X Discovery Holdings has no debt.
  • C4X Discovery Holdings currently has no debt however we can't compare to 5 years ago as we have no data for that period.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • C4X Discovery Holdings has sufficient cash runway for more than 3 years based on current free cash flow.
  • C4X Discovery Holdings has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -29.5% each year.
X
Financial health checks
We assess C4X Discovery Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. C4X Discovery Holdings has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is C4X Discovery Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from C4X Discovery Holdings dividends. Estimated to be 41.57% next year.
If you bought £2,000 of C4X Discovery Holdings shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate C4X Discovery Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate C4X Discovery Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:C4XD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 0.8%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 699 Stocks 4.5%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.1%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AIM:C4XD Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2021-07-31 0.20 1.00
2020-07-31 0.17 1.00
2019-07-31 0.14 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as C4X Discovery Holdings has not reported any payouts.
  • Unable to verify if C4X Discovery Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of C4X Discovery Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as C4X Discovery Holdings has not reported any payouts.
Future Payout to shareholders
  • The company is expected to pay a dividend in 3 years whilst incurring a loss, therefore the dividend is not expected to be well covered.
X
Income/ dividend checks
We assess C4X Discovery Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can C4X Discovery Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. C4X Discovery Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of C4X Discovery Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Clive Dix
COMPENSATION £183,000
AGE 64
TENURE AS CEO 3.3 years
CEO Bio

Dr. Clive James Dix, Ph.D. has been the Chief Executive Officer of C4X Discovery Holdings plc since May 4, 2016. Dr. Dix co-founded Convergence Pharmaceuticals Limited and served as its Chief Executive Officer. He served as Senior Vice President of Research and Development at Chiron Pharmaceuticals Limited. Previously, he was a Co-founder and the Chief Executive Officer of PowderMed Ltd. Dr. Dix's prior positions include Senior Vice President, Research and Development and a Board Member of PowderJect Pharmaceuticals plc until its acquisition by Chiron Vaccines in 2003. He serves as a Non-Executive Chairman of Modern Biosciences plc and Auralis Ltd. He serves as the Chairman of Centauri Therapeutics Limited. He serves as the Chairman of Touchlight Genetics Limited and Calchan Ltd. Dr. Dix served as the Executive Chairman of C4X Discovery Holdings plc since September 3, 2014. He served as the Chairman of Crescendo Biologics Limited. He has an in-depth understanding of all facets of the drug discovery and development process, having led projects and portfolios from conception through to Phase III in a range of therapeutic areas including cardiovascular, respiratory, inflammatory and infectious diseases with over 30 years’ experience in the pharmaceutical and biotechnology business encompassing leadership, project management and drug development. He was the UK Research Director for Glaxo Wellcome. As a Research Director at Glaxo Wellcome, Dr. Dix was responsible for running Powderject Pharmaceuticals PLC's research site at Stevenage in the United Kingdom, managing over 900 scientists. He served as the Biology Director at Glaxo Wellcome to other senior scientific positions, including Head of Biochemistry at Ciba-Geigy Pharmaceuticals. He served as Chairman of the UK BioIndustry Association from 2008 to 2010. He served as the Non-Executive Chairman of C4X Discovery Holdings plc until November 19, 2015. He has been a Director of C4X Discovery Limited and C4X Discovery Holdings plc since September 3, 2014. He also co-chaired Glaxo Wellcome's management group that had responsibility for overseeing all research projects across the world. Dr. Dix has been a Non Executive Director at Carrick Therapeutics, Ltd. since August 2017. He serves as a Director of PowderMed Ltd. and Convergence Pharmaceuticals Limited. He serves as a Member of Life Sciences Advisory Board at Advent Venture Partners. He served as an Executive Director of Chiron Pharmaceuticals Limited. Dr. Dix holds a Ph.D. in Pharmacology and a B.Sc., with honors.

CEO Compensation
  • Clive's compensation has increased whilst company is loss making.
  • Clive's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the C4X Discovery Holdings management team in years:

3
Average Tenure
56
Average Age
  • The tenure for the C4X Discovery Holdings management team is about average.
Management Team

Clive Dix

TITLE
CEO & Director
COMPENSATION
£183K
AGE
64
TENURE
3.3 yrs

Brad Hoy

TITLE
CFO & Director
COMPENSATION
£171K
AGE
56
TENURE
2.8 yrs

Justian Fox

TITLE
Chief Scientific Officer & Director
COMPENSATION
£180K
AGE
44
TENURE
3.8 yrs

Bhavna Hunjan

TITLE
Head of Corporate Strategy & Development
TENURE
2.2 yrs

Mark Sullivan

TITLE
Company Secretary
Board of Directors Tenure

Average tenure and age of the C4X Discovery Holdings board of directors in years:

2.8
Average Tenure
58
Average Age
  • The average tenure for the C4X Discovery Holdings board of directors is less than 3 years, this suggests a new board.
Board of Directors

Eva-Lotta Allan Coulter

TITLE
Non-Executive Chairman of the Board
COMPENSATION
£7K
AGE
60
TENURE
1.1 yrs

Clive Dix

TITLE
CEO & Director
COMPENSATION
£183K
AGE
64
TENURE
4.9 yrs

Brad Hoy

TITLE
CFO & Director
COMPENSATION
£171K
AGE
56
TENURE
2.8 yrs

Justian Fox

TITLE
Chief Scientific Officer & Director
COMPENSATION
£180K
AGE
44
TENURE
2.8 yrs

Alex Stevenson

TITLE
Non-Executive Director
COMPENSATION
£15K
AGE
47
TENURE
4.9 yrs

Natalie Walter

TITLE
Non-Executive Director
COMPENSATION
£3K
TENURE
1.1 yrs

Harry Finch

TITLE
Non Executive Director
COMPENSATION
£31K
AGE
70
TENURE
4.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
06. Mar 19 Buy Clive Dix Individual 06. Mar 19 06. Mar 19 40,650 £0.62 £25,000
22. Oct 18 Buy Justian Fox Individual 19. Oct 18 19. Oct 18 5,900 £0.87 £5,115
X
Management checks
We assess C4X Discovery Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. C4X Discovery Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Such Is Life: How C4X Discovery Holdings (LON:C4XD) Shareholders Saw Their Shares Drop 61%

But long term C4X Discovery Holdings plc (LON:C4XD) shareholders have had a particularly rough ride in the last three year. … Check out our latest analysis for C4X Discovery Holdings C4X Discovery Holdings isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … In the last three years, C4X Discovery Holdings saw its revenue grow by 120% per year, compound.

Simply Wall St -

Did C4X Discovery Holdings plc (LON:C4XD) Insiders Buy Up More Shares?

So before you buy or sell C4X Discovery Holdings plc (LON:C4XD), you may well want to know whether insiders have been buying or selling. … But logic dictates you should pay some attention to whether insiders are buying or selling shares. … Overall, C4X Discovery Holdings insiders were net buyers last year

Simply Wall St -

Is C4X Discovery Holdings plc's (LON:C4XD) CEO Paid At A Competitive Rate?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Clive Dix's Compensation Compare With Similar Sized Companies. … At the time of writing our data says that C4X Discovery Holdings plc has a market cap of UK£51m, and is paying total annual CEO compensation of UK£174k

Simply Wall St -

What Investors Should Know About C4X Discovery Holdings plc's (LON:C4XD) Financial Strength

The direct benefit for C4X Discovery Holdings plc (LON:C4XD), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. … Is C4XD right in choosing financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

When Will C4X Discovery Holdings plc (LON:C4XD) Breakeven?

C4X Discovery Holdings plc's (LON:C4XD):. … C4X Discovery Holdings plc operates as a drug discovery and development company in the United Kingdom. … In this article, I will touch on the expectations for C4XD’s growth and when analysts expect the company to become profitable.

Simply Wall St -

Is It The Right Time To Buy C4X Discovery Holdings plc (LON:C4XD)?

C4X Discovery Holdings plc (LON:C4XD), a healthcare services company based in United Kingdom,. … Check out our latest analysis for C4X Discovery Holdings? … Is C4X Discovery Holdings still cheap

Simply Wall St -

C4X Discovery Holdings plc's (LON:C4XD) Earnings Dropped -27.46%, Did Its Industry Show Weakness Too?

Given that these figures may be somewhat short-term thinking, I have created an annualized five-year figure for C4X Discovery Holdings's earnings, which stands at -UK£3.60M. … AIM:C4XD Income Statement Mar 19th 18 We can further evaluate C4X Discovery Holdings's loss by looking at what the industry has been experiencing over the past few years. … This shows that whatever near-term headwind the industry is enduring, it’s hitting C4X Discovery Holdings harder than its peers.What does this mean?

Simply Wall St -

C4X Discovery Holdings plc (LON:C4XD): Should The Recent EPS Drop Worry You?

Below, I will assess C4X Discovery Holdings plc's (AIM:C4XD) track record on a high level, to give you some insight into how the company has been performing against its historical trend and its industry peers. … View our latest analysis for C4X Discovery Holdings Was C4XD's recent earnings decline worse than the long-term trend and the industry? … For C4X Discovery Holdings, the latest earnings -£5.6M, which, against last year’s figure, has become more negative.

Simply Wall St -

Breaking Down C4X Discovery Holdings plc's (AIM:C4XD) Ownership Structure

See our latest analysis for C4XD AIM:C4XD Ownership Summary Nov 20th 17 Institutional Ownership C4XD's 49.93% institutional ownership seems enough to cause large share price movements in the case of significant share sell-off or acquisitions by institutions, particularly when there is a low level of public shares available on the market to trade. … Although C4XD has a high institutional ownership, such stock moves, in the short-term, are more commonly linked to a particular type of active institutional investors – hedge funds. … This is a positive sign for potential investors as these firms play an important role in aligning company policy with shareholder returns.What this means for you: C4XD's considerably high level of institutional ownership calls for further analysis into its margin of safety.

Simply Wall St -

Is C4X Discovery Holdings plc (AIM:C4XD) On The Right Side Of Disruption?

AIM:C4XD PE PEG Gauge Nov 6th 17 Healthcare tech companies are typically trading at a PE of 40x, higher than the rest of the UK stock market PE of 19x. … If your initial investment thesis is around the growth prospects of C4XD, there are other healthcare tech companies that have delivered higher growth, and perhaps trading at a discount to the industry average. … Although its growth has delivered lower growth relative to its healthcare tech peers in the near term, the market may be pessimistic on the stock, leading to a potential undervaluation.

Simply Wall St -

Company Info

Description

C4X Discovery Holdings plc operates as a drug discovery and development company in the United Kingdom. The company has a suite of proprietary technologies across the drug discovery process, including Taxonomy 3, a novel in silico platform technology that utilises proprietary ground-breaking mathematical algorithms to perform complex multivariate analysis of genetic data; Conformetrix, a technology platform which allows 3D-shapes of free drug molecules to be measured from experimental data, giving medicinal chemists new and unprecedented insights into the behaviour and physical properties of drug molecules; and MolPlex. Its product pipeline comprises Oral Orexin-1, an antagonist for the treatment of addiction; Oral GPR142 and GLP-1, an agonist for the treatment of type 2 diabetes; Oral Nrf-2 activators and IL-17 inhibitors for the treatment of inflammatory disorders; and various products for the treatment of oncology. The company has collaboration agreement with the University of Bristol, the University of Reading, the University of Oxford, and the University of Manchester; and a discovery partnership with Horizon Discovery Group plc to develop synthetic lethality targets in oncology. The company was formerly known as Schosween 24 plc and changed its name to C4X Discovery Holdings plc October 2014. C4X Discovery Holdings plc was founded in 2007 and is based in Manchester, the United Kingdom.

Details
Name: C4X Discovery Holdings plc
C4XD
Exchange: AIM
Founded: 2007
£25,717,723
57,792,636
Website: http://www.c4xdiscovery.com
Address: C4X Discovery Holdings plc
Manchester One,
53 Portland Street,
Manchester,
Greater Manchester, M1 3LD,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM C4XD Ordinary Shares London Stock Exchange AIM Market GB GBP 23. Oct 2014
Number of employees
Current staff
Staff numbers
47
C4X Discovery Holdings employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/08/18 21:49
End of day share price update: 2019/08/16 00:00
Last estimates confirmation: 2019/06/25
Last earnings filing: 2019/04/30
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.